The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

Phase 0 Completed 30 enrolled Richard W Yee, MD Novartis Pharmaceuticals · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the clinical efficacy of 5% lifitegrast ophthalmic solution in subjects with dry eye disease secondary to ocular Graft-versus-Host Disease compared to placebo.

Timeline

Start: 2022-10-22
Primary completion: 2024-04-30
Completion: 2024-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lifitegrast	Unknown	5 %	Other

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

Summary

Timeline

Drugs

Indications